The program times are listed in Central European Time (CEST)
INDUSTRY SESSION
Date
Wed, 02.06.2021
Session Type
INDUSTRY SESSION
Session Time
13:20 - 14:50
Room
Hall A
Session Description
ORAL GLP-1RA: NOVEL BUT NOT NEW - Industry Symposium Supported by Novo Nordisk
Session description - Discuss how semaglutide can be delivered as an oral formulation and drive early GLP-1RA initiation while also benefiting individuals with longstanding type 2 diabetes. Large peptide molecules generally require injection for medication delivery. This session will introduce you to the technology that facilitates semaglutide to be delivered as a simple, daily oral tablet. Explore frequently asked questions from people with diabetes and learn where an oral GLP-1RA fits into their daily routine.
INDUSTRY SESSION
ORAL GLP-1RA: NOVEL BUT NOT NEW
Date
Wed, 02.06.2021
Session Name
Lecture Time
13:20 - 13:20
INDUSTRY SESSION
Industry Symposium Supported by Novo Nordisk
Date
Wed, 02.06.2021
Session Name
Lecture Time
13:20 - 13:20
INDUSTRY SESSION
Welcome and introduction
Date
Wed, 02.06.2021
Session Name
Lecture Time
13:20 - 13:25
INDUSTRY SESSION
Oral peptide, how is that possible?
Date
Wed, 02.06.2021
Session Name
Lecture Time
13:25 - 13:32
INDUSTRY SESSION
Early treatment: could GLP-1RA be initiated earlier?
Date
Wed, 02.06.2021
Session Name
Lecture Time
13:32 - 13:46
Presenter
Authors
INDUSTRY SESSION
Treating patients with longstanding T2D: can this group benefit from oral semaglutide?
Date
Wed, 02.06.2021
Session Name
Lecture Time
13:46 - 14:00
Presenter
Authors
INDUSTRY SESSION
Questions about GLP-1RA
Date
Wed, 02.06.2021
Session Name
Lecture Time
14:00 - 14:25
Presenter